CPSO Proposes Eight-Week Limit and No Take-Home Doses for Safer Supply

Ontario's medical regulator has called an October 13, 2026 special board meeting to consider changes to safer-supply prescribing. The notice, dated September 25, and accompanying College of Physicians and Surgeons of Ontario (CPSO) board package describe a proposal, not a decision already in force. Community pharmacies dispensing these prescriptions are a key audience for the forthcoming outcome.

What the proposal would change

• Safer-supply opioids would be prescribed alongside opioid agonist therapy (OAT), during its dose-titration period, for no more than eight weeks.
• Prescriptions would identify their safer-supply purpose and specify no take-home doses, supporting observed consumption by regulated health professionals.
• Patients would receive an in-person clinical assessment at least monthly.

CPSO's briefing anticipates a transition to compliance by November 16, while recognizing that tapering some patients on high doses could take longer. That timetable remains part of the proposal and must not be presented as an approved pharmacy deadline. Source: briefing note, pages 5–6.

The pharmacy implications are still being worked through

OCP's September board report says it is accelerating preparation for possible CPSO changes, with attention to pharmacy readiness, access and patient communication. Source: OCP board report.

For pharmacy teams, the practical questions include consultation space, staffing, coordination with prescribers and what a transition would mean for each patient. Those are planning questions, not evidence that a new dispensing rule has already been adopted. The regulator's stated aim of reducing diversion also should not be confused with proof of the clinical effect of the proposed model.

Why this is a physician-policy proposal, not a dispensing order

The CPSO board package asks directors whether to approve draft revisions to physicians’ prescribing obligations. It does not itself amend pharmacy law or direct an individual pharmacist to change an existing prescription. The proposed language would require the prescriber to identify a safer-supply prescription and specify “no carries,” so that the intended supervised-consumption arrangement is communicated to the dispensing team. Whether and how a pharmacy could safely provide that service depends on final policy wording, patient circumstances, staffing and the regulator’s implementation guidance. OCP says it is preparing for those practical effects, but has not yet issued a final operational rule based on this proposal.

What the transition would have to address

CPSO says its objective is to reduce diversion risk while connecting safer-supply prescribing more closely to opioid agonist therapy. It anticipates a small number of physicians and pharmacies would be directly affected, primarily those already involved in OAT. The briefing envisages compliance by November 16 if the changes are adopted, but explicitly recognizes that tapering some patients receiving high doses of short-acting opioids may take longer. This caveat is important: a proposed date does not replace individualized assessment, communication or continuity planning for people already in care.

The draft also distinguishes monthly in-person clinical assessment from a more comprehensive assessment by the physician at least every three months when safer supply is prescribed on an ongoing basis. Those are proposed prescriber expectations, not tasks a pharmacist should assume have occurred without documentation or communication. A pharmacy-facing implementation question is how to resolve a prescription whose directions, observed-dosing arrangements or patient plan are unclear before a dispensing decision is made. That is a reason for coordinated follow-up with the prescriber and the patient—not for a blanket interruption of therapy based on a headline.

Practice guidance for pharmacists

Pharmasist suggests preparing for the decision without pre-empting it:

• Check the October 13 decision and final wording before changing a protocol on the basis of this proposal.
• Identify who will coordinate questions with local prescribers and the regulator.
• Review the staffing and access questions that supervised consumption could raise in your setting.
• Explain the distinction between a proposal and a current requirement when patients ask about headlines.
• Do not initiate blanket prescription changes or abrupt discontinuation solely because of this news item.

Members of the public can apply to observe the meeting through the CPSO meeting page; registration closes October 8 at 4 p.m. The next authoritative step is the board's decision.